NTRK1 (Neurotrophic Tyrosine Kinase Receptor 1) encodes the TrkA (Tropomyosin Receptor Kinase A) receptor, a high-affinity receptor tyrosine kinase for nerve growth factor (NGF). TrkA is the principal receptor mediating NGF's effects on neuronal survival, differentiation, axonal guidance, and synaptic plasticity. In the adult nervous system, TrkA is expressed primarily in basal forebrain cholinergic neurons, sympathetic neurons, and nociceptive sensory neurons, making it a central player in both neurodegenerative disease and pain disorders.
The NGF/TrkA signaling axis is one of the most extensively studied neurotrophin systems and represents a foundational target for neuroprotective strategies in Alzheimer's disease, where loss of cholinergic innervation is a cardinal feature. Dysregulation of TrkA signaling has also been implicated in Parkinson's disease, amyotrophic lateral sclerosis, and peripheral neuropathies.
| Attribute |
Value |
| Protein Name |
Tropomyosin Receptor Kinase A (TrkA) |
| Gene Symbol |
NTRK1 |
| UniProt ID |
P04629 |
| Alternative Names |
TrkA, Trk, p140-NTRK1 |
| Molecular Weight |
~87 kDa (full-length) |
| Protein Length |
796 amino acids |
| Chromosomal Location |
1q21-q22 |
| Subcellular Location |
Plasma membrane, endosomes, nucleus |
| Protein Family |
Trk (Tropomyosin Receptor Kinase) family |
| Ligand |
Nerve Growth Factor (NGF) |
¶ Domain Architecture
TrkA possesses a canonical receptor tyrosine kinase structure:
Extracellular Domain (~320 residues):
- Leucine-rich motifs (LRR1-3): Three leucine-rich repeat segments flanking cysteine-rich clusters
- Two cysteine-rich clusters: Form disulfide-bonded structures mediating ligand-independent dimerization
- Two immunoglobulin-like domains (Ig1, Ig2): Ig2 (C2-type) is the primary NGF binding site; Ig1 may interact with cell adhesion molecules
- The extracellular domain controls ligand specificity — TrkA binds NGF exclusively among neurotrophins
Transmembrane Domain:
- Single alpha-helical transmembrane segment
- Anchors receptor to plasma membrane
- Transduces ligand-binding conformational change across membrane
Intracellular Domain (~320 residues):
- Tyrosine kinase domain: Catalyzes autophosphorylation and substrate phosphorylation
- Activation loop: Regulates kinase activity; phosphorylated on Y670, Y674, Y675 upon activation
- Multiple tyrosine residues: Y496, Y705, Y706, Y751, Y754, Y785, Y791 — each docking site for specific SH2/PTB domain proteins
- C-terminal tail: Regulatory phosphorylation sites and protein interaction motifs
TrkA activation follows a well-characterized sequence:
- NGF binding: Two NGF molecules bind two TrkA receptors, inducing receptor dimerization
- Autophosphorylation: Intracellular kinase domains trans-autophosphorylate (Y670, Y674, Y675 in the activation loop)
- Docking site creation: Phosphotyrosines recruit adaptor proteins (Shc, PLC-γ1, etc.)
- Signal diversification: Multiple downstream cascades initiated simultaneously
NGF binding to TrkA activates three major signaling cascades:
1. Ras/MAPK (RAF/MEK/ERK) Pathway:
- TrkA autophosphorylation recruits Shc and Grb2/SOS
- Ras activation → RAF → MEK → ERK1/2
- Promotes neuronal survival via ERK1/2-mediated transcription
- Drives long-term phenotypic changes including gene expression for differentiation
2. PI3K/Akt Pathway:
- Phosphorylated TrkA recruits PI3K via Gab1/2 adaptors
- PIP2 → PIP3 via PI3K; Akt recruited to membrane
- Akt phosphorylates pro-apoptotic proteins (Bad, FOXO, GSK3β)
- Strong anti-apoptotic, pro-survival signaling — the primary survival pathway
3. PLC-γ1 Pathway:
- Phosphorylated Y785 recruits PLC-γ1
- PLC-γ1 hydrolyzes PIP2 → DAG + IP3
- DAG activates PKC; IP3 triggers Ca²⁺ release from ER
- PKC activation modulates ion channels, transcription factors, and cytoskeletal dynamics
Neuronal survival:
- NGF/TrkA is the archetypal survival signal for specific neuronal populations
- Retrograde axonal transport of NGF from targets to cell bodies is required for survival
- TrkA-mediated survival depends primarily on PI3K/Akt signaling
Differentiation and development:
- Guides axonal growth toward NGF-producing target fields
- Promotes phenotypic differentiation of sympathetic and sensory neurons
- Regulates synaptic specificity during development
Synaptic plasticity:
- TrkA is present at synapses in the adult brain
- NGF/TrkA signaling modulates synaptic strength and plasticity in the basal forebrain
- Cholinergic neuron function — particularly hippocampal and cortical plasticity — depends on TrkA
Pain and thermoregulation:
- TrkA on nociceptive C-fibers mediates inflammatory and heat pain
- NGF/TrkA is upregulated in injured peripheral nerves, driving hyperalgesia
- TrkA antagonists (e.g., tanezumab, fulranumab) are in development for chronic pain
The NGF/TrkA axis is central to AD pathogenesis because basal forebrain cholinergic neurons (BFCNs) — which degenerate early in AD — depend on NGF/TrkA signaling for their survival and function:
Cholinergic neuron vulnerability:
- BFCNs project to hippocampus and cortex, regions critical for memory
- These neurons synthesize and release acetylcholine, essential for attention and memory encoding
- BFCNs express high levels of TrkA and require retrograde NGF transport from target regions
- Age-related decline in NGF/TrkA signaling contributes to cholinergic dysfunction
Mechanisms of dysfunction:
- Reduced TrkA receptor expression on cholinergic neurons in aging and AD
- Impaired axonal transport of NGF from cortex to basal forebrain
- Altered NGF protein levels and processing in AD brains
- TrkA signaling becomes uncoupled from downstream survival pathways (PI3K/Akt)
Therapeutic strategies:
- Exogenous NGF: Delivered intraparenchymally or via gene therapy; showed modest effects on cognition, but significant side effects (pain, weight loss) from off-target NGF effects on sensory neurons
- TrkA agonists: Small molecule agonists designed to selectively activate TrkA on cholinergic neurons without the sensory side effects
- AAV2-NGF gene therapy (CERE-110): Phase 2 trial showed acceptable safety and some signal for cognitive stabilization
Current challenges:
- NGF does not cross the blood-brain barrier (BBB)
- NGF causes painful hyperalgesia when reaching peripheral sensory neurons
- TrkA agonists must achieve selectivity and brain penetration
TrkA signaling influences PD through multiple mechanisms:
Dopaminergic neuron support:
- TrkA is expressed in subsets of dopaminergic neurons in the substantia nigra pars compacta
- NGF/TrkA signaling promotes survival of dopaminergic neurons in culture and animal models
- Strategies to enhance TrkA signaling in the nigrostriatal system are under investigation
Inflammatory modulation:
- NGF is upregulated in Parkinson's disease brains and CSF
- TrkA signaling on glial cells may modulate neuroinflammation
- Anti-inflammatory effects of TrkA activation are being explored
Neurotrophin co-expression:
- Co-administration of BDNF (via NTRK2) and NGF (via NTRK1) may provide synergistic neuroprotection
- Gene therapy approaches delivering multiple neurotrophins are in development
- Motor neurons express TrkA in some contexts, particularly during development
- NGF/TrkA signaling may influence motor neuron survival
- Evidence is less robust than for BDNF (NTRK2) in ALS
- Therapeutic targeting remains speculative
This is the most clinically advanced application of TrkA targeting:
- NGF overexpression drives pathological pain and hyperalgesia
- TrkA antagonists (monoclonal antibodies like tanezumab) neutralize NGF, reducing pain
- NGF-neutralizing antibodies have reached phase 3 trials for osteoarthritis, cancer pain, and chronic low back pain
- Side effect of rapidly progressive osteoarthritis (joint destruction) led to FDA hold in 2010-2012, partially lifted subsequently
Aiming to activate TrkA signaling for neuronal survival in AD and PD[@iyerr2023]:
| Strategy |
Candidate |
Status |
Notes |
| Small molecule agonists |
Various |
Preclinical |
Limited by selectivity and BBB penetration |
| Peptide agonists |
YEP series |
Preclinical |
Mimic NGF active site |
| Gene therapy (AAV) |
AAV2-NGF |
Phase 2 |
CERE-110 — mixed results |
| Cell therapy |
NGF-secreting cells |
Preclinical |
Encapsulated cell devices |
| Allosteric modulators |
PAMs |
Discovery |
Positive allosteric modulators |
Opposite strategy — blocking NGF/TrkA for analgesic effect:
| Candidate |
Company |
Status |
Indication |
| Tanezumab |
Pfizer/Eli Lilly |
Phase 3 |
Osteoarthritis, chronic pain |
| Fulranumab |
Amgen/Janssen |
Phase 2 |
Chronic pain |
| BIIB074 (gosuranemab) |
Biogen |
Phase 2 |
Trigeminal neuralgia |
| DV-1178 |
Domain/Takeda |
Discontinued |
Phase 2 for pain |
| Trial |
Agent |
Target |
Status |
Outcome |
| NCT00240617 |
NGF (intracerebroventricular) |
TrkA |
Phase 1 |
Terminated — side effects |
| NCT00876824 |
AAV2-NGF (CERE-110) |
TrkA |
Phase 2 |
Safe, some cognitive benefit signal |
| NCT01530529 |
NGF (intraventricular) |
TrkA |
Phase 1 |
Pain, weight loss — halted |
| Various |
Small molecule TrkA agonists |
TrkA |
Preclinical |
Active |
flowchart TD
A["NGF Dimer"] --> B["TrkA Dimerization<br/>(two receptors bound)"]
B --> C["Autophosphorylation<br/>(Y670, Y674, Y675)"]
C --> D1["Shc recruitment"]
C --> D2["PLC-gamma1 recruitment"]
C --> D3["PI3K recruitment"]
D1 --> E1["Ras/MAPK Pathway<br/>Gene expression, differentiation"]
D2 --> E2["PKC/Ca2+ Pathway<br/>Ion channel modulation"]
D3 --> E3["PI3K/Akt Pathway<br/>Neuronal survival"]
E3 --> F1["Bad inactivation"]
E3 --> F2["FOXO inhibition"]
E3 --> F3["GSK3beta inhibition"]
F1 --> G["Anti-apoptotic signaling"]
F2 --> G
F3 --> G
style A fill:#e1f5fe,stroke:#333
style G fill:#c8e6c9,stroke:#333
- NGF — Primary ligand for TrkA
- BDNF — Binds TrkB (NTRK2), not TrkA
- NTRK2 — TrkB receptor for BDNF and NT-4
- p75NTR — NGF co-receptor (p75 neurotrophin receptor)
- Shc — Adaptor protein recruited to phosphorylated TrkA
- PLC-gamma1 — Effector enzyme downstream of TrkA